Halofuginone inhibits NF-κB and p38 MAPK in activated T cells

Journal of Leukocyte Biology

Volumn 80, Issue 2, 2006, Pages 399-406

  Leiba, M ^a,b   Cahalon, L ^c   Shimoni, A ^a,b   Lider, O ^c   Zanin Zhorov, A ^c   Hecht, I ^c   Sela, U ^c   Vlodavsky, I ^d   Nagler, A ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

TGF ; TNF

Indexed keywords

CD3 ANTIBODY; GAMMA INTERFERON; HALOFUGINONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

APOPTOSIS; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; HYPERSENSITIVITY; IN VIVO STUDY; INCUBATION TIME; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE ACTIVATION; DOSE RESPONSE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALIA;

APOPTOSIS; CHEMOTAXIS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LYMPHOCYTE ACTIVATION; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PIPERIDINES; QUINAZOLINES; QUINAZOLINONES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 33748853355     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0705409     Document Type: Article

References (41)

1. Pines, M., Snyder, D., Yarkoni, S., Nagler, A. (2003) Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol. Blood Marrow Transplant. 9, 417-425.
2. Granot, I., Halevy, O., Hurwitz, S., Pines, M. (1993) Halofuginone: an inhibitor of collagen type I synthesis. Biochim. Biophys. Acta 1156, 107-112.
3. Pines, M., Nagler, A. (1998) Halofuginone: a novel antifibrotic therapy. Gen. Pharmacol. 30, 445-450.
4. Nagler, A., Miao, H. Q., Aingorn, H., Pines, M., Genina, O., Vlodavsky, I. (1997) Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler. Thromb. Vasc. Biol. 17, 194-202.
5. Nagler, A., Katz, A., Aingorn, H., Miao, H. Q., Condiotti, R., Genina, O., Pines, M., Vlodavsky, I. (1997) Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone. Kidney Int. 52, 1561-1569.
6. Elkin, M., Reich, R., Nagler, A., Aingorn, E., Pines, M., de-Groot, N., Hochberg, A., Vlodavsky, I. (1999) Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin. Cancer Res. 5, 1982-1988.
7. Abramovitch, R., Itzik, A., Harel, H., Nagler, A., Vlodavsky, I., Siegal, T. (2004) Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model-an MRI study. Neoplasia 6, 480-489.
8. Xavier, S., Piek, E., Fujii, M., Javelaud, D., Mauviel, A., Flanders, K. C., Samuni, A. M., Felici, A., Reiss, M., Yarkoni, S., Sowers, A., Mitchell, J. B., Roberts, A. B., Russo, A. (2004) Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-β signaling by halofuginone. J. Biol. Chem. 279, 15167-15176.
9. Flanders, K. C. (2004) Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol. 85, 47-64.
10. Batra, V., Musani, A. I., Hastie, A. T., Khurana, S., Carpenter, K. A., Zangrilli, J. G., Peters, S. P. (2004) Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-β1, TGF-β2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on α-smooth muscle actin and collagen III synthesis by primary human lung fibroblasts. Clin. Exp. Allergy 34, 437-444.
11. Lider, O., Cahalon, L., Gilat, D., Hershkoviz, R., Siegel, D., Margalit, R., Shoseyov, O., Cohen, I. R. (1995) A disaccharide that inhibits tumor necrosis factor α is formed from the extracellular matrix by the enzyme heparanase. Proc. Natl. Acad. Sci. USA 92, 5037-5041.
12. Campbell, J., Ciesielski, C. J., Hunt, A. E., Horwood, N. J., Beech, J. T., Hayes, L. A., Denys, A., Feldmann, M., Brennan, F. M., Foxwell, B. M. (2004) A novel mechanism for TNF-α regulation by p38 MAPK: involvement of NF-κ B with implications for therapy in rheumatoid arthritis. J. Immunol. 173, 6928-6937.
13. Nanki, T., Lipsky, P. E. (2000) Cutting edge: stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation. J. Immunol. 164, 5010-5014.
14. Ghosh, S., May, M. J., Kopp, E. B. (1998) NF-κ B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225-260.
15. Kishimoto, T., Taga, T., Akira, S. (1994) Cytokine signal transduction. Cell 76, 253-262.
16. Kopp, E., Ghosh, S. (1994) Inhibition of NF-κ B by sodium salicylate and aspirin. Science 265, 956-959.
17. Kopp, E. B., Ghosh, S. (1995) NF-κ B and rel proteins in innate immunity. Adv. Immunol. 58, 1-27.
18. Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., Karin, M. (1995) Immunosuppression by glucocorticoids: inhibition of NF-κ B activity through induction of I κ B synthesis. Science 270, 286-290.
19. Ray, A., Prefontaine, K. E. (1994) Physical association and functional antagonism between the p65 subunit of transcription factor NF-κ B and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA 91, 752-756.
20. Scheinman, R. I., Cogswell, P. C., Lofquist, A. K., Baldwin Jr., A. S. (1995) Role of transcriptional activation of I κ B α in mediation of immunosuppression by glucocorticoids. Science 270, 283-286.
21. Bharti, A. C., Aggarwal, B. B. (2002) Chemopreventive agents induce suppression of nuclear factor-κB leading to chemosensitization. Ann. N. Y. Acad. Sci. 973, 392-395.
22. Griffin, J. D. (2001) Leukemia stem cells and constitutive activation of NF-κB. Blood 98, 2291-2298.
23. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., Anderson, K. C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071-3076.
24. Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., Elliott, P. J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622.
25. Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y. T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Schlossman, R., Munshi, N. C., Hideshima, T., Anderson, K. C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377-2380.
26. LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C. S., Adams, J., Gupta, D., Richardson, P. G., Munshi, N. C., Anderson, K. C. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62, 4996-5000.
27. Elkin, M., Miao, H. Q., Nagler, A., Aingorn, E., Reich, R., Hemo, I., Dou, H. L., Pines, M., Vlodavsky, I.. (2000) Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J. 14, 2477-2485.
28. Abramovitch, R., Dafni, H., Neeman, M., Nagler, A., Pines, M. (1999) Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1,321-329.
29. Gavish, Z., Pinthus, J. H., Barak, V., Ramon, J., Nagler, A., Eshhar, Z., Pines, M. (2002) Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 51, 73-83.
30. Aggarwal, B. B. (2000) Apoptosis and nuclear factor-κ B: a tale of association and dissociation. Biochem. Pharmacol. 60, 1033-1039.
31. Kitajima, I., Soejima, Y., Takasaki, I., Beppu, H., Tokioka, T., Maruyama, I. (1996) Ceramide-induced nuclear translocation of NF-κ B is a potential mediator of the apoptotic response to TNF-α in murine clonal osteoblasts. Bone 19, 263-270.
32. Wu, M., Lee, H., Bellas, R. E., Schauer, S. L., Arsura, M., Katz, D., Fitzgerald, M. J., Rothstein, T. L., Sherr, D. H., Sonenshein, G. E. (1996) Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J. 15, 4682-4690.
33. Lin, K. I., DiDonato, J. A., Hoffmann, A., Hardwick, J. M., Ratan, R. R. (1998) Suppression of steady-state, but not stimulus-induced NF-κB activity inhibits αvirus-induced apoptosis. J. Cell Biol. 141, 1479-1487.
34. Furukawa, F., Matsuzaki, K., Mori, S., Tahashi, Y., Yoshida, K., Sugano, Y., Yamagata, H., Matsuushita, M., Seki, T., Inagaki, Y., Nishizawa, M., Fujisawa, J., Inoue, K. (2003) p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 38, 879-889.
35. Roberts, A. B. (1999) TGF-β signaling from receptors to the nucleus. Microbes Infect. 1, 1265-1273.
36. Massague, J. (2000) How cells read TGF-β signals. Nat. Rev. Mol. Cell Biol. 1, 169-178.
37. Attisano, L., Wrana, J. L. (2002) Signal transduction by the TGF-β superfamily. Science 296, 1646-1647.
38. McGaha, T., Kodera, T., Phelps, R., Spiera, H., Pines, M., Bona, C. (2002) Effect of halofuginone on the development of tight skin (TSK) syndrome. Autoimmunity 35, 277-282.
39. Yamaguchi, K., Shirakabe, K., Shibuya, H., Irie, K., Oishi, I., Ueno, N., Taniguchi, T., Nishida, E., Matsumoto, K. (1995) Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270, 2008-2011.
40. Hanafusa, H., Ninomiya-Tsuji, J., Masuyama, N., Nishita, M., Fujisawa, J., Shibuya, H., Matsumoto, K., Nishida, E. (1999) Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression. J. Biol. Chem. 274, 27161-27167.
41. Hecht, I., Hershkoviz, R., Shivtiel, S., Lapidot, T., Cohen, I. R., Lider, O., Cahalon, L. (2004) Heparin-disaccharide affects T cells: inhibition of NF-κB activation, cell migration, and modulation of intracellular signaling. J. Leukoc. Biol. 75, 1139-1146.